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Abstract
Introduction: Rheumatoid arthritis (RA) is a T-cell-mediated systemic autoimmune disease, characterized by
synovium inflammation and articular destruction. Bone marrow mesenchymal stem cells (MSCs) could be effective
in the treatment of several autoimmune diseases. However, there has been thus far no report on umbilical cord
(UC)-MSCs in the treatment of RA. Here, potential immunosuppressive effects of human UC-MSCs in RA were
evaluated.
Methods: The effects of UC-MSCs on the responses of fibroblast-like synoviocytes (FLSs) and T cells in RA patients
were explored. The possible molecular mechanism mediating this immunosuppressive effect of UC-MSCs was
explored by addition of inhibitors to indoleamine 2,3-dioxygenase (IDO), Nitric oxide (NO), prostaglandin E2 (PGE2),
transforming growth factor b1 (TGF-b1) and interleukin 10 (IL-10). The therapeutic effects of systemic infusion of
human UC-MSCs on collagen-induced arthritis (CIA) in a mouse model were explored.
Results: In vitro, UC-MSCs were capable of inhibiting proliferation of FLSs from RA patients, via IL-10, IDO and TGF-
b1. Furthermore, the invasive behavior and IL-6 secretion of FLSs were also significantly suppressed. On the other
hand, UC-MSCs induced hyporesponsiveness of T cells mediated by PGE2, TGF-b1 and NO and UC-MSCs could
promote the expansion of CD4
+ Foxp3
+ regulatory T cells from RA patients. More importantly, systemic infusion of
human UC-MSCs reduced the severity of CIA in a mouse model. Consistently, there were reduced levels of
proinflammatory cytokines and chemokines (TNF-a, IL-6 and monocyte chemoattractant protein-1) and increased
levels of the anti-inflammatory/regulatory cytokine (IL-10) in sera of UC-MSCs treated mice. Moreover, such
treatment shifted Th1/Th2 type responses and induced Tregs in CIA.
Conclusions: In conclusion, human UC-MSCs suppressed the various inflammatory effects of FLSs and T cells of RA
in vitro, and attenuated the development of CIA in vivo, strongly suggesting that UC-MSCs might be a therapeutic
strategy in RA. In addition, the immunosuppressive activitiy of UC-MSCs could be prolonged by the participation of
Tregs.
Introduction
Rheumatoid arthritis (RA) is a chronic and systemic disease
that primarily attacks synovial joints, leading to articular
destruction and functional disability. RA imparts a massive
burden on health services worldwide. Efforts to discover
new target therapies have achieved considerable success.
For instance, TNF-a inhibitors and B-cell-depleting thera-
pies have benefited many RA patients [1,2]. However, these
approaches are expensive and none of the currently widely
used biological agents reaches longterm drug-free remis-
sion [3,4]. Therefore, it is important to develop new and
more effective therapy for RA.
In RA, proinflammatory cytokines, such as TNF-a,I L - 6 ,
IL-1b and IL-17, play dominant pathological roles.
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been linked to pathogenesis of RA [5-7]. Furthermore, evi-
dence is accumulating that a defect in number or function
of regular T cells (Tregs) is important in the immune
imbalance that culminates in RA [8,9]. The fibroblast-like
synoviocytes (FLSs) are resident cells of synovial joints,
involved in pannus formation, and are key players in the
destruction of cartilage and bone in RA joint [10]. The
ability of FLSs to stimulate both inflammation and tissue
damage suggests that this cell type may be another critical
target for the treatment of inflammatory arthritis [11].
Mesenchymal stem cells (MSCs) are cells of stromal
origin that can exert profound immunosuppression by
modulating T and B cell proliferation and differentia-
tion, dendritic cell maturation and NK activity. These
immunoregulatory properties encouraged a possible use
of these cells to modulate autoimmune responses and
in the treatment of autoimmue diseases [12,13]. To
date, the experience of MSCs in the treatment of RA is
limited to a few cases, with controversial results from
preclinical models [14-18]. As of yet, the most common
source of MSCs has been bone marrow. However, aspir-
ating bone marrow is an invasive procedure. In addi-
tion, the number and the differentiating potential of
bone marrow MSCs (BM-MSCs) decrease with age
[19,20]. In contrast, the umbilical cord is a postnatal
organ discarded after birth. The collection of umbilical
cord MSCs (UC-MSCs) does not require any invasive
procedure. In addition to the well-documented self-
renewal and multipotent differentiation properties, UC-
MSCs possess immunoregulatory capacities that have
been permissive to allogeneic transplantation [21].
Given these characteristics, particularly the plasticity
and developmental flexibility, the UC-MSCs are now
considered an alternative source of stem cells and
deserve to be examined in long-term clinical trials [22].
However, very little is known about UC-MSCs, and of
note, there has been no report about UC-MSCs in the
treatment of RA.
In this study, we reported our findings of the suppres-
sive effect of UC-MSCs on the proliferation, invasive
behavior and inflammatory responses of FLSs from RA
patients. We also demonstrated that UC-MSCs could
inhibit activation of T cells and induced Tregs expres-
sion in RA. More importantly, in mice, systemic infusion
of UC-MSCs significantly reduced the severity of col-
lagen-induced arthritis (CIA). In addition, the possible
mechanism(s) underlying the UC-MSCs-mediated inhi-
bitory effect were explored.
Materials and methods
Isolation, culture and differentiation of UC-MSCs
This study was approved by the Research Ethics Com-
mittee at the Beijing University People’sH o s p i t a l
(FWA00001384). All participants provided written
informed consent. Fresh human umbilical cords (n =5 )
were obtained after birth and collected in Hanks’
Balanced Salt Solution at 4°C. Umbilical arteries and
veins were removed, and the remaining tissue was trans-
ferred into a sterile container in Minimum Essential
Medium (MEM-a) (Invitrogen, Carlsbad, CA, USA)
with antibiotics (penicillin 100 IU/ml, streptomycin
100 μg/ml; Invitrogen) and was then dissected into
cubes of about 0.5 cm
3 and centrifuged at 250 g for five
minutes. The explants were transferred to a 25 cm
2
flask containing the MEM-a along with 10% fetal bovine
serum (Invitrogen). They were left undisturbed for three
to four days to allow migration of cells from the
explants, at which point the media was replaced. They
were re-fed and passaged as necessary. After three
passages, the cells were harvested and stained with
fluorescein-conjugated monoclonal antibody against
CD14, CD45, CD34, HLA-DR, CD44, CD73, CD90 and
CD29. (BD Pharmingen, San Diego, CA, USA), followed
by analyzing with flow cytometry (FACS Calibur,
Becton, Dickinson and Company, Franklin Lakes, NJ,
USA). The UC-MSCs were then used directly for cul-
ture or stored in liquid nitrogen for later use.
Osteogenic differentiation
To induce osteogenic differentiation, third- to seventh-
passage cells were treated with osteogenic medium for
three weeks with medium changes twice weekly. Osteo-
genesis was assessed at weekly intervals. Osteogenic
medium consists of MEM-a supplemented with 0.1 μM
dexamethasone (Sigma, St. Louis, MO, USA), 10 mM
b-glycerol phosphate (Sigma) and 0.2 mM ascorbic acid
(Sigma).
Adipogenic differentiation
To induce adipogenic differentiation, second- to fifth-
passage cells were treated with adipogenic medium for
three weeks. Medium changes were carried out twice
weekly and adipogenesis was assessed at weekly intervals.
Adipogenic medium consists of MEM-a supplemented
with 0.5 mM 3-isobutyl-1-methylxanthine (Sigma), 1 μM
hydrocortisone (Sigma), 0.1 mM indomethacin (INDO,
Sigma) and 10% rabbit serum (Sigma).
Isolation and culture of FLSs and T cells from RA patients
Synovial tissues were obtained from patients with RA
(n = 5, females, aged from 30 to 60 years) and traumatic
patients without arthritis (n =4 )a tt i m eo fk n e er e p l a -
cement surgery. Peripheral blood mononuclear cells
( P B M C s )i s o l a t e df r o m1 0R Ap a t i e n t s( f e m a l e s ,a g e d
from 35 to 56 years) by density sedimentation on Ficoll-
Hypaque gradients were separated immunomagnetically
into T cells by negative selection using the RosetteSep
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instructions (Stem Cell Technologies, Vancouver, BC,
Canada). The procedure was approved by the ethical
committee at the Beijing University People’sH o s p i t a l
(FWA00001384). All patients gave written informed
consent. All RA patients fulfilled the criteria of the
American College of Rheumatology for the classification
of RA [23]. Isolation and culture of FLSs were described
previously [24].
Proliferation assay
UC-MSCs were all irradiated (30 Gray) before being
co-cultured with FLSs or T cells. Each culture was per-
formed in triplicate in 96-well flat-bottom microtitre
plates (Corning, New York, NY, USA) in a total volume of
0.2 ml MEM-a supplemented with 10% FBS. UC-MSCs
were added to the plates at different ratios to FLSs or
T cells with the stimulation of TNF-a (PeproTech Inc,
Rocky Hill, NJ, USA; 20 ng/ml) or PHA (Sigma, 2 μg/ml).
The group in which FLSs or T cells were cultured alone
served as negative controls. The plates were incubated in a
humidified atmosphere of 5% CO2 at 37 ℃ for five days.
UC-MSCs were added on Day 4 (1:1 to FLSs) to the total
five-day coculture to explore the effects of UC-MSCs on
FLSs at late time point. To evaluate the possible mechan-
isms of the suppressive effect of UC-MSCs, inhibitors of
indoleamine 2,3-dioxygenase (IDO), nitric oxide (NO),
prostaglandin E2 (PGE2), transforming growth factor b1
(TGF-b1) and IL-10 (that is, 1-methyl-DL-tryptophan
(1-MT) (Sigma), N-nitro-L-arginine methyl ester
(L-NAME) (Sigma), INDO, anti-TGF-b1m A b( R & D ,
Minneapolis, MN, USA) and anti-IL-10 mAb (R&D)) were
added to co-cultures at appropriate concentrations.
To compare the suppressive capacity of CD4
+CD25
+
T cells from CIA mice treated with human UC-MSCs
and phosphate buffered saline (PBS), the regulatory
T cells (Tregs) were purified from the spleens by mag-
netic cell sorting using the CD4
+CD25
+ regulatory T-
cell isolation kit (Miltenyi Biotec, Bergisch Gladbach,
Germany) in accordance with the manufacturer’s
instructions. Tregs (1 × 10
5 cells) from human
UC-MSC-treated or untreated mice were added to the
CD4
+CD25
- responder T cells (1 × 10
5 cells), stimulated
with anti-CD3 Ab (BD Pharmingen, 5 μg/ml) and anti-
CD28 Ab (BD Pharmingen, 5 μg/ml) for five days.
Eighteen hours before the end of culture, 1 μCi of (
3H)
thymidine (GE Healthcare, Amersham, Buckinghamshire,
UK) was added to each well. Cells were harvested onto
nitrocellulose, and the radioactivity incorporated was
counted in a scintillation counter. The FLSs and T cell
proliferation was represented as the incorporated radio-
activity in counts per minute (c. p. m.) and the results
were expressed as c. p. m. ± S.D. of the mean. All experi-
ments in our study including the following study were
performed independently at least three times for each
point described.
Transwell culture
FLSs and T cells were cultivated in the lower chamber
of a 6.5 mm or 4.26 mm diameter Transwell plate with
a0 . 4μm pore size membrane (Corning). UC-MSCs
were seeded onto the Transwell membrane of the inner
chamber one to two hours before the beginning of the
culture. Control culture did not contain UC-MSCs, or
UC-MSCs were added directly to the FLSs or T cells.
After three or five days, cytokine production or prolif-
eration of FLSs and T cells was determined. The inva-
sive behavior of FLSs was assayed using the Cytoselect
24-Well Cell Migration and Invasion Assay (Cell Biolabs
Inc, San Diego, CA, USA) according to the manufac-
turer’s instructions. Briefly, UC-MSCs (150,000), which
were fixed with 1% paraformaldehyde, were distributed
to wells with FLSs (150,000), or UC-MSCs (150,000)
were added in the lower well of the invasion plate, with
FLSs (150,000) alone in the well inserts. Forty-eight
hours later, the inserts were stained with the cell stain
solution and the OD 560 nm was measured in a plate
reader.
Induction and treatment of CIA
Animal experimental protocols were approved by the
Ethics Committee of Beijing University People’s Hospital
(FWA00001384). DBA/1 mice (six to eight weeks old;
SLAC Laboratory Animal Center, Shanghai, China) were
injected subcutaneously with 150 μgo fb o v i n et y p eI I
collagen (CII) (Chondrex, Redmond, WA, USA) emulsi-
fied in Freund’s complete adjuvant, and then given sub-
cutaneous booster injections with 75 μgo fC I Ii n
Freund’s incomplete adjuvant.
Based on clinical scores, mice were monitored for
signs of arthritis onset. Clinical arthritis was scored on a
scale of 0 to 3, where 0 = no swelling, 1 = slight swel-
ling and erythema, 2 = pronounced edema, and 3 =
joint rigidity. Each limb was graded, and the grades
were summed to yield the arthritis score for each animal
(maximum possible score 12 per animal) [25].
Treatment was begun after the onset of disease (Day
31), when arthritis had become established (arthritis
score ≥1). As previously described [16], mice were
injected intraperitoneally each day for five days with
phosphate buffered saline (PBS) alone, with 1 × 10
6
human UC-MSCs, or with 1 × 10
6 human FLSs isolated
from traumatic joints respectively. In addition, 1 × 10
6
dead human UC-MSCs, which were fixed by 4% parafor-
maldehyde, were injected intraperitoneally into mice
with CIA each day for five days. Animals were sacrificed
62 days after immunization wirh CII and their joints
were examined in serial sections.
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reactivity, CIA mice treated with UC-MSCs or not were
intradermally injected with 10 μgC I I / 1 0μlP B Si nt h e
right ear and with 10 μl PBS in the left ear. Ear swelling
was measured 48 hours later with a spring-loaded
micrometer.
Histologic analysis
Formalin-fixed limbs were decalcified and paraffin-
embedded using standard histologic techniques. Serial
4 μm sections were cut and stained with hematoxylin
and eosin to examine morphologic features and assess
the histologic arthritis score. Histopathologic changes
are scored using the following parameters. Sections were
analyzed microscopically for the degree of inflammation
and for cartilage and bone destruction according to the
method reported previously [26], using the following
scale: 0 = normal synovium, 1 = synovial membrane
hypertrophy and cell infiltrates, 2 = pannus and cartilage
erosion, 3 = major erosion of cartilage and subchondral
bone, and 4 = loss of joint integrity and ankylosis. Each
joint was scored separately by two individuals unaware
of the treatment protocol.
To trace the migration of transplanted cells in vivo,
analysis with mAb against human nuclei (Chemicon
International, Temecula, CA, USA) was performed
following the manufacturer’s instructions to detect
UC-MSCs in heart, kidney, spleen and joints of mice
treated with UC-MSCs.
Cytokine quantification
After 72 hours of co-culture with or without TNF-a or
PHA stimulation, fresh supernatant was collected.
Quantitative analyses of IL-6 production were per-
formed by enzyme-linked immunosorbent assay (ELISA)
using commercially available kits (R&D). TNF-a and
Matrix metalloproteinase 9 (MMP9) quantification were
performed on the Luminex-100 system, and the R&D
Fluorokine MAP Human Base Kit A or Human MMP
MultiAnalyte Profiling Base Kit (R&D) was used. Super-
natants of UC-MSCs, FLSs and T cells that were cul-
tured alone served as controls. Cytokine and chemokine
levels in the serum of mice with CIA were determined
by sandwich ELISA using capture/biotinylated detection
antibodies obtained from BD PharMingen.
Flow cytometric analysis
Tregs were stained with anti-CD4-FITC. Then, cells
w e r ef i x e da n dp e r m e a b i l i z e db yF i x / P e r mb u f f e r
(eBioscience, San Diego, CA, USA) and stained for anti-
forkhead box P3 (Foxp3)-PE. Mice Th1, Th2 or Th17
cells in spleen were stained for anti-CD4-APC, then
washed with FACS buffer (PBS plus 1% BSA) and fixed
in PBS containing 2% paraformaldehyde. Subsequently,
cells were stained for anti-IFN-g-PE, anti-IL-4-PE or
anti-IL-17-PE in FACS buffer containing 0.1% saponin.
An appropriate isotype-matched control antibody was
used in all FACS analyses. All antibodies were from BD
Pharmingen except anti-Foxp3 (eBioscience). Cells were
analyzed on a FACS Calibur flow cytometer using Cell
Quest software (Becton, Dickinson and Company).
Statistical analysis
Data were presented as mean ± S.D. The difference
between treatment and control groups was analyzed by
Mann-Whitney U test. P < 0.05 was considered significant.
Results
Expansion of UC-MSCs in vitro
The UC-MSCs were successfully isolated and expanded
from all the umbilical cords. They had a fibroblast-like
morphology, uniformly negative for CD14, CD45, CD34
and HLA-DR, but positive for CD44, CD73, CD90 and
CD29 (Figure 1a, b). Functionally, they were capable of dif-
ferentiating into adipocytes and osteocytes (Figure 1c, d).
UC-MSCs inhibited proliferation of FLSs from RA patients
The FLSs are resident cells of synovial joints, recog-
nized to play an important role in inflammation and
joint destruction of RA. Therefore, we attempted to
determine the effects of UC-MSCs on the FLSs derived
from RA patients. The FLSs isolated from RA patients
responded positively to TNF-a (20 ng/ml) when com-
pared with control (11,440 ± 2,452 vs. 1,985 ± 516,
P = 0.000). The UC-MSCs significantly inhibited the
proliferation of TNF-a-stimulated-FLSs in the cell-to-
cell contact and the transwell system, and the effect
was dose dependent (Figure 2a). Moreover, such inhi-
bitory effects were profound even when UC-MSCs
were added on the fourth day in an experiment of five-
day coculture (11,110 ± 2,142 vs. 5,379 ± 1,435, P =
0.000, Figure 2b).
Soluble factors involved in the suppressive effect of
UC-MSCs on the proliferation of FLSs from RA patients
Since IDO, NO, PGE2, IL-10 and TGF-b1 are key factors
in MSCs-mediated inhibition [27-30], co-culture experi-
ments were performed using the corresponding inhibi-
tors. They included 1-MT (1 mM), an inhibitor of IDO
enzymatic activity, INDO (5 μM), an inhibitor of PGE2
synthesis, L-NAME (1 mM), a specific inhibitor of NO
synthase, anti-TGF-b1 monoclonal antibody (10 μg/ml)
and anti-IL-10 monoclonal antibody (10 μg/ml). As
s h o w ni nF i g u r e2 c ,T N F - a-mediated FLSs proliferation
could be sufficiently restored by anti-IL-10, 1-MT and
anti-TGF-b1, respectively, suggesting that those soluble
factors were the key mediators in UC-MSCs-mediated
inhibition. However, IDO and PGE2 were not found
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not shown).
UC-MSCs suppressed the invasive behavior and MMP9
expression of FLSs from RA patients
The invasive property of RA patients-derived FLSs has
been shown to correlate with the disease severity and
radiographic damage [31]. The MMPs are key mediators
of the invasive phenotype of FLSs [32]. Therefore, we
further investigated the effect of UC-MSCs on the invasive
behavior of FLSs by the Cell Migration/Invasion Assay,
and the MMP9 secretion of FLSs. As a result, the invasive
behavior of FLSs was significantly inhibited when they
were co-cultured with UC-MSCs in the cell-to-cell contact
(1.27 ± 0.21 vs. 0.57 ± 0.09) and the transwell system
(1.27 ± 0.21 vs. 0.65 ± 0.11), (Figure 3a). Consistently, the
production of MMP9 was significantly downregulated by
co-culture with UC-MSCs in both systems (Figure 3b).
UC-MSCs suppressed the inflammatory response of FLSs
from RA patients
FLSs from RA patients confer both inflammation and
tissue damage. One of the critical mediators of inflam-
mation in RA is the proinflammatory cytokine IL-6.
Interestingly, the UC-MSCs could downregulate the
IL-6 production in the transwell but not the cell-to-cell
contact system (Figure 3c) both in single time point and
in dynamic study (Figure 3d).
UC-MSCs induced hyporesponsiveness of T lymphocytes
from RA patients
Several studies have shown that BM-MSCs could induce
hyporesponsiveness of T lymphocytes. However, such
investigations are limited for UC-MSCs, particularly so far
no studies have been done in RA. As shown in Figure 4a,
proliferation of T lymphocytes from RA patients was sig-
nificantly suppressed by UC-MSCs with a dose-dependent
manner, regardless in the cell-to-cell contact or the trans-
well system. Subsequently, we tried to determine which
soluble factors involved in the suppressive process. As
shown in Figure 4b, the suppressive effect of UC-MSCs on
T cells mainly depended on TGF-b1( P =0 . 0 0 0 ) ,P G E 2
(P = 0.000) and NO (P = 0.000).
In RA pathogenesis, TNF-a plays a central role in the
pro-inflammatory cytokine cascade [33]. We then asked
whether UC-MSCs-mediated hyporesponsiveness of
T cells was associated with TNF-a production. As a
result, we observed that UC-MSCs potently decreased
Figure 1 Characteristics of UC-MSCs. (a) Cell culture of passage 3. Original magnification × 40. The cells had a fibroblast-like morphology.
(b) Flow cytometric analysis of surface-marker expression on UC-MSCs. They were negative for CD14, CD45, CD34 and HLA-DR, but positive for
CD44, CD73, CD90 and CD29. The dotted line is the isotype control. (c) Oil red O staining of UC-MSCs after the induction of adipogenic
differentiation for 21 days. Arrows indicate lipid roplets. Original magnification × 40. (d) Osteogenic differentiation of UC-MSCs staining for
alkaline phosphatase. Arrows indicate the accumulation of intracytoplasmic alkaline phosphatase of osteoblast. Original magnification × 40.
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tact and the transwell system, especially in PHA acti-
vated T cells (Figure 4c).
UC-MSCs induced Tregs from RA patients
Given the concept that Tregs play a critical role in the
maintenance of self-immune tolerance in RA [34],
UC-MSCs exert an immunoregulatory function on FLSs
and T cells. The next intriguing question is whether
UC-MSCs play a role in the induction of Tregs in RA.
Recent studies demonstrated that not all CD4
+CD25
bright
cells coexpressed Foxp3, while some Foxp3
+ cells resided
in the CD25
dim or CD25
- population [35]. In this study,
the expression of FoxP3 on CD4
+ T cells (CD4
+Foxp3
+)
was defined as Tregs. Notably, the percentages of CD4
+
Foxp3
+ T cells were significantly higher in the presence
of UC-MSCs, irrespective of PHA stimulation (Figure 5).
UC-MSCs prevented tissue damage in CIA
The immunosuppressive effects of UC-MSCs on T cells
and FLSs in human RA promoted us to investigate the
potential therapeutic effects of UC-MSCs in CIA, which
is an arthritis model that shares a number of clinical,
histologic and immunologic features of RA. As shown in
Figure 6a, the severity of CIA was progressively attenu-
ated in UC-MSCs treated mice, as compared with PBS
treated mice. Moreover, the therapeutic effect was speci-
fic to viable human UC-MSCs, because dead human
UC-MSCs and human FLSs from traumatic patients
without arthritis failed to prevent the progression of
arthritis. The therapeutic effects of UC-MSCs on CIA in
mice were further verified by histological examination at
the endpoint of clinical study. We observed that control
mice exhibited a marked mononuclear cell infiltration,
severe synovitis, pannus formation and bone erosion. In
contrast, the majority of joints from mice injected with
UC-MSCs had normal morphology with a smooth
articulation cartilage surface, and an absence of inflam-
matory cell infiltrate and pannus formation (Figure 6b).
UC-MSCs treatment reduced inflammatory responses
in CIA
The clinical amelioration and histological verification in
CIA in mice strongly suggests that UC-MSCs are a potent
tolerogenic agent that could suppress the autoimmune
responses in CIA. We next investigated the effect of
UC-MSCs on production of inflammatory mediators that
are mechanistically linked to CIA. As shown in Figure 6c,
human UC-MSCs injection significantly downregulated
protein expression of various proinflammatory cytokines
and chemokines (TNF-a, IL-6 and monocyte chemoat-
tractant protein-1 (MCP-1)), as well as upregulted the
anti-inflammatory/regulatory cytokine (IL-10).
Figure 2 Effects of UC-MSCs on FLSs proliferation. (a) Compared
with the control, TNF-a (20 ng/ml) significantly induced the
proliferation of FLSs after five days of culture. UC-MSCs inhibited
TNF-a-stimulated-FLSs proliferation in a dose-dependent fashion in
the cell-to-cell contact system and also the transwell system. All the
data are expressed as the mean ± SD of more than three
independent experiments. **P < 0.01 vs. the controls. (b) FLSs
proliferation was significantly inhibited when UC-MSCs were added
on the fourth day after the initiation of stimulation in the five-day
coculture experiment. All the data are expressed as the mean ± SD
of more than three independent experiments. **P < 0.01 vs. the
control. (c) Anti-IL-10, 1-MT and anti-TGF-b1 restored FLSs
proliferation. FLSs (1 × 10
4) were activated with TNF-a in the
presence or absence of irradiated MSCs (1 × 10
4) in 96-well plates.
Anti-IL-10 (10 μg/Ml), 1-MT (1 mM) and TGF-b1 antibody (10 μg/mL)
were added for five days. The incorporation of (
3H)-thymidine is
shown by CPM. All the data are expressed as the mean ± SD of
more than three independent experiments. **P < 0.01.
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We traced the UC-MSCs in the recipient organism by the
detection of mAb against human nuclei in heart, kidney,
spleen and joints of mice treated with UC-MSCs. As a
result, human UC-MSCs were not detectable by immu-
nohistochemistry in the joints of UC-MSC-treated mice,
suggesting that injected UC-MSCs did not restore tissue
integrity by mechanisms of tissue repair (data not
s h o w n ) .H o w e v e r ,w ew e r ea b l et od e t e c tt h e s ec e l l sa t
intermediate time points during the course of the disease
in spleen (Figure 6d), but not in other organs, which sug-
gested that UC-MSCs possibly circulate through the
bloodstream after the transfusion, after Day 7, human
UC-MSCs were negative in the spleen.
Lymphocyte priming was not affected by UC-MSCs
DTH responses, as evident from the data shown in
Figure 6e, suggested that UC-MSCs did not affect
priming of antigen-specific T lymphocytes. Because the
DTH response was positively recalled using murine CII
in mice in all experimental groups, and no statistically
significant differences between groups were observed,
albeit the response tended to be less vigorous in MSC-
treated mice.
UC-MSCs treatment shifted Th1 toward Th2 and
induced Tregs in CIA
Initially, CIA was considered to be a Th1-mediated disease;
however, recent studies have revealed that another T cell
subset, -Th17 cells, is also pathogenic in CIA [5,6]. It raises
the possibility that the interventions targeting both the
IFN-g (Th1) and the IL-17 (Th17) axes might be more pro-
mising therapeutic approaches for CIA [36]. By analyzing
the intracellular cytokine expression in the spleen CD4
+
T cells, we demonstrated that UC-MSCs could downregu-
late IFN-g-producing Th1 cells (Figure 7a) and tend to
decrease IL-17-producing Th17 cells (Figure 7c), while
upregulated IL-4-producing Th2 cells (Figure 7b).
Several studies have shown that IL-10 producing Tregs
confer significant protection against CIA by inhibiting
Figure 3 Effects of UC-MSCs on the invasive behavior and IL-6 production of FLSs in vitro. (a) Invasive behavior of FLSs in Matrigel matrix
was measured in the transwell system. Forty-eight hours after seeding on matrix the number of FLSs grown through Matrigel and transwell
membrane was detected. All the data are expressed as the mean ± SD of more than three independent experiments. ** P < 0.01 vs. the control.
(b) FLSs (2 × 10
4) from RA patients and UC-MSCs (2 × 10
4) were separated in the transwell system or cocultured in the cell-to-cell contact
system in 24-well plates. After 72 hours, MMP9 in culture supernatants were determined. MMP9 production was inhibited both in the cell-to-cell
contact system and the transwell system. All the data are expressed as the mean ± SD of more than three independent experiments. **P < 0.01,
vs. FLSs alone. (c) FLSs (2 × 10
4) from RA patients and UC-MSCs (2 × 10
4) were separated in the transwell system or cocultured in the cell-to-cell
contact system in 24-well plates. After 72 hours, IL-6 in culture supernatants was determined. IL-6 production was inhibited in the transwell
system. All the data are expressed as the mean ± SD of more than three independent experiments. **P < 0.01 vs. FLSs alone. (d) Time course of
IL-6 production. At different time points, IL-6 was downregulated only in the transwell system. **P < 0.01, *P < 0.05 vs. FLSs alone, respectively.
All the data are expressed as the mean ± SD of more than three independent experiments.
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Page 7 of 13the activation of autoreactive Th1 cells [37,38]. Downre-
gulation of the inflammatory Th1 and the elevated IL-10
levels by UC-MSCs prompted us to further investigate
the effect of Tregs in immunosuppressant action of
UC-MSCs in vivo.A ss h o w ni nF i g u r e7 d ,w ef o u n dt h a t
there were significantly higher numbers of CD4
+Foxp3
+
Tregs in spleen and peripheral blood in the UC-MSC-
treated mice than the PBS treated mice. Moreover,
CD4
+CD25
+T cells isolated from human UC-MSC-trea-
ted mice functioned as suppressive Treg cells, since they
inhibited the proliferation of syngeneic T cells stimulated
with CD3 and CD28 (Figure 7e).
Discussion
In the present study, we provided evidence that
UC-MSCs can exert a profound inhibitory effect on FLSs
and T cells from RA patients. They could suppress prolif-
eration, the invasive behavior and inflammatory
responses of FLSs, inhibit activation of T cells and induce
the Tregs expression. Furthermore, we showed that
UC-MSC mediated suppression on T cells and FLSs pro-
liferation through several soluble factors, including IDO,
PGE2, NO, IL-10 and TGF-b1, respectively. Systemic
infusion of UC-MSCs significantly reduced the severity
of CIA in mice. The improvement of clinical manifesta-
tion was accompanied by the decreased secretion of var-
ious inflammatory cytokines and chemokines, and the
downregulated Th1/Th17 cells. Furthermore, in the
UC-MSCs treated mice, the expansion of Th2/Tregs and
the production of anti-inflammatory IL-10 were elevated.
MSCs have the capability of self-renewal and differen-
tiation into various lineages of mesenchymal tissues.
Moreover, MSCs have been consistently shown to exert a
potent immunosuppressive effect superior in magnitude
to any other immunosuppressive cell types thus far
described [39]. Compared with those from bone marrow,
MSCs derived from UC have higher proliferative potency,
stronger differentiation capacity, and lower risk for viral
contamination. However, their therapeutic potential in
the treatment of RA has not been investigated.
Recently, the FLSs have been shown to straddle both
components of RA, the immune activation and tissue
destruction. Therefore, targeting FLSs may abrogate the
disease progression [40]. Our data demonstrated that
UC-MSCs could inhibit the proliferation of TNF-a sti-
mulated FLSs. Notably, delayed addition of UC-MSCs
maintained such inhibitory effects, suggesting that the
transplantation of these cells is practicable and effective
for treatment of RA. Interestingly, the invasive behavior
of FLSs was inhibited by UC-MSCs, indicating that
UC-MSCs might be potentially important in the inhibi-
tion of bone erosion in RA.
T cells are believed to play a critical role in orchestrat-
ing the inflammatory response in RA. Suppression of
Figure 4 Effects of UC-MSCs on T cell proliferation and cytokine
production. (a) UC-MSCs inhibited PHA-induced T-cell proliferation in
a dose-dependent fashion. T cells (1 × 10
5) were activated with PHA in
the presence or absence of irradiated UC-MSCs in different ratio in
96-well plates. Inhibition of T cell proliferation was also found in the
transwell system. All the data are expressed as the mean ± SD of more
than three independent experiments. **P < 0.01, vs. the control.
(b) Anti-TGF-b1, INDO and L-NAME restored T-cell proliferation. T cells
(1 × 10
5) were activated with PHA in the presence or absence of
irradiated UC-MSCs (2 × 10
4) in 96-well plates. The incorporation of
(
3H)-thymidine is shown by CPM. All the data are expressed as the
mean ± SD of more than three independent experiments. **P < 0.01.
(c) UC-MSCs suppressed T cells from producing pro-inflammatory
cytokine TNF-a. T cells (1 × 10
6) from RA patients and UC-MSCs
(5 × 10
4) were separated in the transwell system or cocultured in the
cell-to-cell contact system in 24-well plates. After 72 hours, TNF-a in
culture supernatants was determined. All the data are expressed as the
mean ± SD of more than three independent experiments. ** P <0 . 0 1 ,
* P < 0.05 vs. the controls, respectively.
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Page 8 of 13T cell responses is of great importance in RA treatment,
as evidenced by the facts that allogeneic BM-MSCs and
hASCs both suppress the responses of CII-reactive
T cells in RA [17,18]. In agreement, we observed that
UC-MSCs could inhibit the PHA-stimulated-T cell pro-
liferation and secretion of TNF-a. Similar to RA, Th1
and Th17 cell-mediated responses play an important
role in the pathogenesis of CIA [41]. Our results
demonstrated that administration of human UC-MSCs
could downregulate IFN-g-producing Th1 cells and tend
to decrease IL-17-producing Th17 cells, while upregu-
late IL-4-producing Th2 cells in mice CIA. Tregs play
an important role in the prevention of autoimmunity,
and it has been demonstrated that they could modulate
the severity of CIA [37,42]. Several studies have shown
that BM-MSCs and hASCs could recruit, regulate and
maintain the T-regulatory phenotype and function over
time [43]. In this study, we found UC-MSCs could also
induce the Tregs, both in vitro and in vivo, suggesting
that the immunosuppressive activity of UC-MSCs could
be prolonged by the participation of Tregs. However,
the observation that the DTH response to the immuniz-
ing antigen existed in UC-MSC-treated mice indicates
that priming of T lymphocytes occurred. Therefore,
maybe a complex mechanism existed in the suppressive
effect of UC-MSCs.
To date, the molecular mechanisms responsible for the
immunosuppressive effects of MSCs have not been com-
pletely understood. In BM-MSCs, there have been no
agreements among different research groups. However,
the main focus is on the soluble factors including IDO,
NO, PGE2, IL-10 and TGF-b1 [27-30]. A recent study
identified TGFb1 as a critical mediator involved in
the suppressive response of human BM-MSCs on
Figure 5 UC-MSCs induced regulatory T cells expansion. T cells (1 × 10
6) isolated from RA patients were cocultured with UC-MSCs (5 × 10
4)
in the absence or presence of PHA in 24-well plates. After three days, regulatory T cells expression was analyzed in the CD4
+ T cell fraction by
flow cytometry. Numbers represent the mean percentage of positive cells from different groups. All the data are expressed as mean c.p.m. ± S.D,
*P < 0.05.
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Page 9 of 13CII-activated PBMCs from RA patients [17]. However,
the TGFb1 blockade did not significantly affect the
immunosuppressive action of hASCs on T cells from RA
patients [18], suggesting that MSCs of different origins
maybe mediated suppression through different cytokines.
In this study, we demonstrated that TGF-b1, PGE2
and NO are potent modulators involved in UC-MSCs
mediated T-cell inhibition, while IDO, TGF-b1 and IL-10
were mainly involved in the suppressive effect of UC-
MSCs on FLSs.
Systemic administration of human UC-MSCs in estab-
lished CIA in mice significantly ameliorated the clinical
and histopathologic severity of the disease. The thera-
peutic effect was xenogeneic, which means that the
Figure 6 UC-MSCs prevented tissue damage and inflammatory responses in CIA. (a) Treatment was begun after the onset of disease
(arthritis score≥1). PBS and PBS containing 1 × 10
6 UC-MSCs were injected intraperitoneally each day for five days to mice with CIA. The severity
of CIA was progressively attenuated in UC-MSCs treated mice, as compared with PBS treated mice. N = 10, **P < 0.01, vs. the PBS controls. All
the data are expressed as the mean ± SD. (b) H & E-stained sagittal sections of joints from CIA mice. PBS treated mice showed a marked
mononuclear cell infiltration, severe synovitis, pannus formation and bone erosion. However, the majority of joints from mice injected with
UC-MSCs had normal morphology with a smooth articulation cartilage surface, and an absence of inflammatory cell infiltrate and pannus
formation. Original magnification × 100. N = 10, **P < 0.01, vs. the PBS controls. All the data are expressed as the mean ± SD. (c) UC-MSCs
treatment reduced inflammatory responses in CIA. There were reduced levels of proinflammatory cytokines and chemokines (TNF-a, IL-6 and
MCP-1) and increased levels of the anti-inflammatory/regulatory cytokine (IL-10) in sera of UC-MSC-treated mice, in comparison with PBS treated
mice. N = 10, ** P < 0.01, * P < 0.05, respectively. All the data are expressed as the mean ± SD. (d) UC-MSCs were detected in the spleen of CIA
mice. mAb against human nuclei was used to detect human UC-MSCs in CIA mice, on Day 3 and Day 7, UC-MSCs were detected in the spleen.
Arrows indicate human UC-MSCs in the spleen. Original magnification × 200. (e) DTH responses in UC-MSC-treated or untreated CII immunized
mice. Values are the mean ± SD. N =5 .
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Page 10 of 13Figure 7 Effects of UC-MSCs on T cell subtypes in CIA model. (a) UC-MSCs downregulated Th1-type response. UC-MSCs decreased the
number of IFNg-producing Th1 cells, n =6 ,* * P < 0.01. All the data are expressed as the mean ± SD. (b) UC-MSCs upregulated Th2-type
response. UC-MSCs increased the number of IL4-producing Th2 cells. N =6 ,* * P < 0.01. All the data are expressed as the mean ± SD.
(c) UC-MSCs tended to decrease Th17-type response. UC-MSCs tend to decrease the number of IL-17-producing Th17 cells. N = 6. All the data
are expressed as the mean ± SD. (d) UC-MSCs treatment induced Tregs in CIA. Percentages of CD4
+FoxP3
+ cells in spleen and peripheral blood
in UC-MSCs treated group were higher than the PBS control group. N =6 ,* * P < 0.01. All the data are expressed as the mean ± SD. (e) As
compared with Tregs isolated from PBS-treated mice, CD4
+CD25
+ T cells isolated from UC-MSC-treated mice functioned as suppressive Tregs,
since they inhibited the proliferation of effective T cells (Teff). N =6 ,* * P < 0.01. All the data are expressed as the mean ± SD.
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Page 11 of 13immunosuppressive action of UC-MSCs is major histo-
compatibility complex unrestricted and that the infused
UC-MSCs are sufficiently well immunotolerated by the
host.
Direct evidence of the beneficial effect is that adminis-
tration of UC-MSCs attenuated systemic inflammation
in CIA in mice. UC-MSCs downregulated the produc-
tion of the proinflammatory cytokines TNF-a,a n dI L - 6
in vitro and in vivo. In addition, MCP-1 is a member of
the CC family and could be induced by inflammatory
cytokines. Several groups have detected MCP-1 in the
synovial fluid of RA patients, with markedly higher con-
centrations than those in other rheumatic diseases,
including osteoarthritis [44]. Therefore, reduction of
MCP-1 could partly explain the absence of inflammatory
infiltrates in the synovium of mice treated with human
UC-MSCs. Moreover, UC-MSCs increased the levels of
the antiinflammatory cytokine IL-10. Aside from its role
as an antiinflammatory factor [45], IL-10 is a signature
cytokine for Tregs, and plays a key role in the control of
self-antigen-reactive T cells in vivo [38]. The upregula-
tion of IL-10 is in line with the induction of Tregs in
vitro and in vivo in our study. Moreover, in our experi-
ments we did not find UC-MSCs in the joint of the CIA
mice. The short-term presence of UC-MSCs in the
spleen suggests that the therapeutic effect of UC-MSCs
does not rely on the capacity to engraft and survive
long-term in the appropriate target organs. More likely,
UC-MSCs could “educate” other cells to inhibit the
pathogenic immune reaction.
Conclusions
In this study, UC-MSCs exerted a profound inhibitory
effect on the proliferation, invasive behavior and inflam-
matory responses of FLSs, suppressed T cell activation
and induced the generation of Tregs. Most importantly,
cell-based therapy using human UC-MSCs significantly
ameliorated CIA in mice. These data suggest that UC-
MSCs might be therapeutic perspectives in RA.
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